2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Tuesday, November 15, 2016

4:30PM-6:00PM: Abstract Number: 3086

Changing Patterns over Time in Opiate Use in U.S. Rheumatoid Arthritis Patients

Rheumatoid Arthritis – Clinical Aspects V: Challenges in the Assessment and Management of Established RA

4:30PM-6:00PM: Abstract Number: 3108

Citrullinated Aggrecan Peptides Are Targets of Auto-Reactive CD4+ T-Cells in Rheumatoid Arthritis

T Cell Biology and Targets in Autoimmune Disease - Oral Session

4:30PM-6:00PM: Abstract Number: 3L

Comparative Cardiovascular Safety of Tocilizumab Vs Etanercept in Rheumatoid Arthritis: Results of a Randomized, Parallel-Group, Multicenter, Noninferiority, Phase 4 Clinical Trial

ACR Late-breaking Abstract Session

4:30PM-6:00PM: Abstract Number: 3093

Comparison of Changes in Cardiovascular Risk-Associated Biomarkers in RA Patients Treated with Anti-TNF or Other Biological Agents: A Metabolic Study from a Randomized Trial

Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy IV: Biomarkers

4:30PM-6:00PM: Abstract Number: 3060

Development and Implementation of a Question-Based Tool Promoting Learning of Relevant Epidemiology and Biostatistics in Rheumatology: The Critical Literature Assessment Skills Support – Rheumatology (CLASS-Rheum) Pilot

Education

4:30PM-6:00PM: Abstract Number: 3076

Development of a Matrix-Binding Interlukin-1 Receptor Antagonist Fusion Protein for Extended Retention in the Joint Tissues

Metabolic and Crystal Arthropathies I: Mechanisms of Disease

4:30PM-6:00PM: Abstract Number: 3078

Diffuse Idiopathic Skeletal Hyperostosis and Diabetes- Using Genetic Risk Scores to Explore the Association

Miscellaneous Rheumatic and Inflammatory Diseases II

4:30PM-6:00PM: Abstract Number: 3085

Do Depression and Anxiety Reduce the Chance of Remission in Rheumatoid Arthritis and Psoriatic Arthritis?

Rheumatoid Arthritis – Clinical Aspects V: Challenges in the Assessment and Management of Established RA

4:30PM-6:00PM: Abstract Number: 3112

DOCK8 Associates with STAT5 and Promotes Regulatory T Cell Function

T Cell Biology and Targets in Autoimmune Disease - Oral Session

4:30PM-6:00PM: Abstract Number: 3104

Early Proteinuria Response in Real Life Situation Predicts Long-Term Lupus Renal Outcome in Ethnically Diverse Group with Biopsy-Proven Nephritis

Systemic Lupus Erythematosus – Clinical Aspects and Treatment IV: Biomarkers

4:30PM-6:00PM: Abstract Number: 2L

Effect of Denosumab Compared with Risedronate in Glucocorticoid-Treated Individuals: Results from the 12-Month Primary Analysis of a Randomized, Double-Blind, Active-Controlled Study

ACR Late-breaking Abstract Session

4:30PM-6:00PM: Abstract Number: 3070

Effect of Sarcopenia, Subcutaneous Adipose Tissue and Abdominal Visceral Fat on Mortality Risk of Community-Dwelling Older Adults: A Population-Based Prospective Cohort Study

Epidemiology and Public Health II: Obesity, Cancer and Mortality

4:30PM-6:00PM: Abstract Number: 3091

Effect of Sarilumab on Circulating Biomarkers of Bone and Joint Destruction in Patients with Rheumatoid Arthritis with Inadequate Response to Methotrexate

Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy IV: Biomarkers

4:30PM-6:00PM: Abstract Number: 4L

Efficacy and Safety Results of Guselkumab, an Anti-IL23 Monoclonal Antibody, in Patients with Active Psoriatic Arthritis over 24 Weeks: A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study

ACR Late-breaking Abstract Session

4:30PM-6:00PM: Abstract Number: 3056

Efficacy of a Work Disability Prevention Program for People with Rheumatic and Musculoskeletal Conditions: A Randomized Controlled Trial

ACR/ARHP Combined Abstract Session: Orthopedics and Rehabilitation

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].